The significance of left ventricular ejection time in heart failure with reduced ejection fraction
Research output: Contribution to journal › Review › Research › peer-review
Standard
The significance of left ventricular ejection time in heart failure with reduced ejection fraction. / Alhakak, Alia S.; Teerlink, John R.; Lindenfeld, Joann; Boehm, Michael; Rosano, Giuseppe M. C.; Biering-Sorensen, Tor.
In: European Journal of Heart Failure, Vol. 23, No. 4, 2021, p. 541-551.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The significance of left ventricular ejection time in heart failure with reduced ejection fraction
AU - Alhakak, Alia S.
AU - Teerlink, John R.
AU - Lindenfeld, Joann
AU - Boehm, Michael
AU - Rosano, Giuseppe M. C.
AU - Biering-Sorensen, Tor
PY - 2021
Y1 - 2021
N2 - Left ventricular ejection time (LVET) is defined as the time interval from aortic valve opening to aortic valve closure, and is the phase of systole during which the left ventricle ejects blood into the aorta. LVET has been used for several decades to assess left ventricular function and contractility. However, there is a recent interest in LVET as a measure of therapeutic action for novel drugs in patients with heart failure with reduced ejection fraction (HFrEF), since LVET is shortened in these patients. This review provides an overview of the available information on LVET including methods of measuring LVET, mechanistic understanding of LVET, association of LVET with outcomes, mechanisms behind shortened LVET in HFrEF and the potential implications of drugs that affect and normalize LVET.[GRAPHICS]
AB - Left ventricular ejection time (LVET) is defined as the time interval from aortic valve opening to aortic valve closure, and is the phase of systole during which the left ventricle ejects blood into the aorta. LVET has been used for several decades to assess left ventricular function and contractility. However, there is a recent interest in LVET as a measure of therapeutic action for novel drugs in patients with heart failure with reduced ejection fraction (HFrEF), since LVET is shortened in these patients. This review provides an overview of the available information on LVET including methods of measuring LVET, mechanistic understanding of LVET, association of LVET with outcomes, mechanisms behind shortened LVET in HFrEF and the potential implications of drugs that affect and normalize LVET.[GRAPHICS]
KW - Left ventricular ejection time
KW - Heart failure
KW - Myotropes
KW - Contractility
KW - Outcomes
KW - CARDIAC MYOSIN ACTIVATOR
KW - MYOCARDIAL PERFORMANCE INDEX
KW - M-MODE ECHOCARDIOGRAPHY
KW - IMAGING M-MODE
KW - OMECAMTIV MECARBIL
KW - INCREASE CONTRACTILITY
KW - INTERVALS
KW - MECHANISMS
KW - RISK
KW - CARVEDILOL
U2 - 10.1002/ejhf.2125
DO - 10.1002/ejhf.2125
M3 - Review
C2 - 33590579
VL - 23
SP - 541
EP - 551
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 4
ER -
ID: 274278065